STOCK TITAN
  1. Home
  2. News
  3. POLBF

POOLBEG PHARMA PLC - POLBF STOCK NEWS

Welcome to our dedicated page for POOLBEG PHARMA PLC news (Ticker: POLBF), a resource for investors and traders seeking the latest updates and insights on POOLBEG PHARMA PLC stock.

Poolbeg Pharma PLC (POLBF) delivers innovative therapies for diseases with critical unmet needs, from cancer immunotherapy complications to rare disorders. This news hub provides investors and industry observers with essential updates on clinical developments, regulatory progress, and strategic partnerships.

Track POLBF's advancements through verified reports on clinical trial results, patent approvals, and collaboration agreements. Our curated collection includes earnings announcements, research breakthroughs, and analysis of pipeline candidates like POLB 001 for cytokine management.

This resource serves as your central reference for understanding Poolbeg Pharma's position in biopharmaceutical innovation. Discover updates spanning orphan drug designations, AI-driven research initiatives, and global licensing opportunities while maintaining compliance with financial disclosure standards.

Bookmark this page for streamlined access to POLBF's evolving story. Check regularly for authoritative reporting on therapies addressing severe influenza, Behçet's disease, and oncology-related challenges.

News

Poolbeg Pharma PLC Announces POLB 001 LPS Trial Data to be Presented at IUIS

Rhea-AI Summary
Poolbeg Pharma (POLB) announces the acceptance of an abstract highlighting the potential of POLB 001 as a groundbreaking therapy at the 18th International Congress of Immunology. POLB 001 is a potential treatment of severe influenza and Cytokine Release Syndrome (CRS) associated with cancer immunotherapies. The poster presentation will discuss POLB 001's positive LPS human challenge trial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Former Amryt Pharma Leadership Team join Poolbeg

Rhea-AI Summary
Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) announces the appointment of key former executives of Amryt Pharma plc to its leadership team. David Allmond, John McEvoy, and Laura Maher will join Poolbeg, enhancing the Company's expertise and capabilities. Allmond will become Chief Business Officer, McEvoy will be SVP, Chief Legal Officer, and Maher will assume the role of Vice President of Clinical Operations. The appointments aim to accelerate Poolbeg's strategy of developing exciting clinical assets and acquiring approved and marketed drugs to generate revenue and fund innovative product development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
News

Poolbeg Pharma PLC Announces POLB 001 Data to be Presented at American Society of Hematology Annual Meeting

Rhea-AI Summary
Poolbeg Pharma announces that an abstract detailing POLB 001's promise as a potential treatment for Cytokine Release Syndrome associated with cancer immunotherapies has been accepted for presentation at the 65th American Society of Hematology Annual Meeting and Exposition. The presentation will provide insight into the results obtained from the POLB 001 LPS human challenge trial, highlighting its potential use in the treatment of CRS. An effective therapy for CRS associated with cancer immunotherapies has the potential to make these treatments more tolerable and widely accessible.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Poolbeg Pharma PLC Announces POLB 001 Oncology Programme Update Meeting

Rhea-AI Summary
Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) will host a meeting on November 6, 2023, to provide an update on its POLB 001 Oncology Programme. The program targets Cytokine Release Syndrome (CRS) associated with cancer immunotherapy treatments. Severe cases of CRS can be life-threatening, and an effective treatment could make these therapies more accessible and reduce side effects. The meeting will feature presentations from key opinion leaders and a patient advocate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Poolbeg Partners with a Nasdaq-Listed Biopharma

Rhea-AI Summary
Poolbeg Pharma partners with a Nasdaq-listed biopharma company for the development of an optimised oral drug to treat a metabolic condition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
-
News

Poolbeg Pharma PLC Announces Favourable Conclusion of Patent Opposition

Rhea-AI Summary
Positive Conclusion Reached in Immunomodulator I Patent Opposition
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Poolbeg Pharma PLC Announces Immunomodulator I Patent Opposition Withdrawal

Rhea-AI Summary
Poolbeg Pharma announces withdrawal of opposition to its European patent, strengthening its intellectual property portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Poolbeg Pharma PLC Announces Interim Results for the Six Months to 30 June 2023

Rhea-AI Summary
Poolbeg Pharma announces unaudited interim results, strong cash balance of £14.1 million as of June 30, 2023. Positive results from POLB 001 trial, potential treatment for severe influenza. Strategic expansion into oncology. AI programme with CytoReason identifies valuable drug targets. Progress on RSV drug targets and treatments. Oral Vaccine consortium progresses to next phase. Continued progress on GLP-1 agonist trial. Professor Brendan Buckley appointed as Non-Executive Director. CEO highlights significant progress and future growth. Investor presentation scheduled. Change of name for Nominated Adviser and Joint Broker.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Poolbeg Pharma PLC Announces AI Led Programme Identifies Influenza Drug Targets

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
AI
News

Poolbeg Pharma PLC - Oral Vaccine Programme Moves Forward

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock POLBF logo
POOLBEG PHARMA PLC

OTC:POLBF

POLBF Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

POLBF Stock Data

59.00M
328.88M
34.22%
3.35%
Biotechnology
Healthcare
Link
United Kingdom
London